Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24 months and immunogenicity of a fifth dose administered at 4 years of age-a phase 3 extension to a randomised controlled trial
Open Access
- 1 January 2017
- journal article
- research article
- Published by Elsevier BV in Vaccine
- Vol. 35 (2), 395-402
- https://doi.org/10.1016/j.vaccine.2016.11.009
Abstract
No abstract availableKeywords
Funding Information
- GSK Vaccines S.r.l.
This publication has 17 references indexed in Scilit:
- Persistence of Bactericidal Antibodies After Infant Serogroup B Meningococcal Immunization and Booster Dose Response at 12, 18 or 24 Months of AgeThe Pediatric Infectious Disease Journal, 2016
- Antibody persistence up to 5 years after vaccination of toddlers and children between 12 months and 10 years of age with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccineHuman Vaccines & Immunotherapeutics, 2015
- Persistence of specific bactericidal antibodies at 5 years of age after vaccination against serogroup B meningococcus in infancy and at 40 monthsCMAJ : Canadian Medical Association Journal, 2015
- Persistence of Bactericidal Antibodies to 5 Years of Age After Immunization With Serogroup B Meningococcal Vaccines at 6, 8, 12 and 40 Months of AgeThe Pediatric Infectious Disease Journal, 2014
- Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster doseCMAJ : Canadian Medical Association Journal, 2013
- Persistence of the immune response at 5 years of age following infant immunisation with investigational quadrivalent MenACWY conjugate vaccine formulationsVaccine, 2012
- Invasive meningococcal disease in England and Wales: Implications for the introduction of new vaccinesVaccine, 2012
- Immunogenicity and Tolerability of Recombinant Serogroup B Meningococcal Vaccine Administered With or Without Routine Infant Vaccinations According to Different Immunization Schedules A Randomized Controlled TrialJama-Journal Of The American Medical Association, 2012
- Antibody Persistence after Serogroup C Meningococcal Conjugate Immunization of United Kingdom Primary‐School Children in 1999–2000 and Response to a Booster: A Phase 4 Clinical TrialClinical Infectious Diseases, 2010
- Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B diseaseVaccine, 2003